Английская Википедия:Danoprevir
Шаблон:Short description Шаблон:Drugbox
Danoprevir (INN)[1] is an orally available[2] 15-membered macrocyclic peptidomimetic inhibitor of NS3/4A HCV protease.[3] It contains acylsulfonamide, fluoroisoindole and tert-butyl carbamate moieties. Danoprevir is a clinical candidate based on its favorable potency profile against multiple HCV genotypes 1–6 and key mutants (GT1b, IC50 = 0.2–0.4 nM; replicon GT1b, EC50 = 1.6 nM).[4] Danoprevir has been evaluated in an open-label, single arm clinical trial in combination with ritonavir for treating COVID-19[5] and favourably compared to lopinavir/ritonavir in a second trial.[6]
History
Danaoprevir was initially developed by Array BioPharma then licensed to Roche for further development and commercialization. In 2013, Danoprevir was licensed to Ascletis by Roche for development and production in China under the tradename Ganovo.[7][8]
References
Further reading
Шаблон:Refbegin Шаблон:Cite journal Шаблон:Refend
Шаблон:RNA antivirals Шаблон:Portal bar
Шаблон:Antiinfective-drug-stub
Шаблон:COVID-19-stub
- Английская Википедия
- Carbamates
- Cyclopropanes
- Anti–hepatitis C agents
- Macrocycles
- NS3/4A protease inhibitors
- Organofluorides
- Pyrrolidines
- Sulfonamides
- Antiviral drugs
- COVID-19 drug development
- Страницы, где используется шаблон "Навигационная таблица/Телепорт"
- Страницы с телепортом
- Википедия
- Статья из Википедии
- Статья из Английской Википедии